Shared on06 Aug 25Fair value Increased 12%
Fulgent Genetics’ fair value has been revised upward, primarily reflecting improved consensus revenue growth forecasts and a higher future P/E multiple, with the analyst price target rising from $22.67 to $25.33. What's in the News Fulgent Genetics expects core revenue of approximately $320 million for full year 2025.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.